Scholarlink

<p><i>Pediococcus pentosaceus</i> species is an emerging probiotic that has recently gained great experimental interest worldwide. This study assessed the probiotic properties, genetic potential, and safety aspects of gut-associated <i>P. pentosaceus</i> for prospective application in animal feed. The in vitro investigation of the <i>P. pentosaceus</i> strain SPARC2 isolated from <i>Nilli Ravi</i> buffaloes gut showed favourable enzymatic (proteolytic, lipolytic, and amylolytic) and antagonistic activities against indicator bacterial strains. Furthermore, strain SPARC2 demonstrated non-toxic and non-hemolytic properties and susceptibility to several tested antibiotics, suggesting its safety for animal consumption. Genome-level analysis revealed that the strains SPARC2 carry no virulence or resistance genes, while numerous probiotic potential genes were detected in the <i>P. pentosaceus</i> SPARC2 genome. The in vivo safety investigation of SPARC2 demonstrated no physiological or haematological dysfunctions in mice. No expression of tumour necrosis factor-alpha (TNF-α) and interleukin-6 (IL-1β) cytokines was observed in the colon tissue of mice. Moreover, <i>P. pentosaceus</i> SPARC2 (1 × 10<sup>9</sup> CFU/g) significantly (<i>p</i> &lt; 0.05) enhanced the blood profile of mice. The advantageous bacterial population was significantly (<i>p</i> &lt; 0.05) enhanced with the administration of (1 × 10<sup>9</sup> CFU/g) SPARC2. The findings indicated that, due to the distinct isolation source and functional and genomic attributes of SPARC2, it may serve as a target-based probiotic in animal feed to enhance health and production performance.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pediococcus pentosaceus strain SPARC2 as a potential probiotic food supplement: genomic insight, probiotic potential, and biosafety profiling in BALB/c mice

  • 期刊论文

  • 发表日期：

    2025年10月14日

查看全文
  • Osama Butt,
  • Laila Jafri,
  • Rehana Rani,
  • Shakira Ghazanfar,
  • Sajid Iqbal

摘要

Pediococcus pentosaceus species is an emerging probiotic that has recently gained great experimental interest worldwide. This study assessed the probiotic properties, genetic potential, and safety aspects of gut-associated P. pentosaceus for prospective application in animal feed. The in vitro investigation of the P. pentosaceus strain SPARC2 isolated from Nilli Ravi buffaloes gut showed favourable enzymatic (proteolytic, lipolytic, and amylolytic) and antagonistic activities against indicator bacterial strains. Furthermore, strain SPARC2 demonstrated non-toxic and non-hemolytic properties and susceptibility to several tested antibiotics, suggesting its safety for animal consumption. Genome-level analysis revealed that the strains SPARC2 carry no virulence or resistance genes, while numerous probiotic potential genes were detected in the P. pentosaceus SPARC2 genome. The in vivo safety investigation of SPARC2 demonstrated no physiological or haematological dysfunctions in mice. No expression of tumour necrosis factor-alpha (TNF-α) and interleukin-6 (IL-1β) cytokines was observed in the colon tissue of mice. Moreover, P. pentosaceus SPARC2 (1 × 109 CFU/g) significantly (p < 0.05) enhanced the blood profile of mice. The advantageous bacterial population was significantly (p < 0.05) enhanced with the administration of (1 × 109 CFU/g) SPARC2. The findings indicated that, due to the distinct isolation source and functional and genomic attributes of SPARC2, it may serve as a target-based probiotic in animal feed to enhance health and production performance.